UNSPSC 51432804: Enalaprilat

This classification denotes an ace inhibitor with the molecular formula C18H24N2O5.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GV0O7ES0R3, chemically known as l-proline, n-((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl- but generally known as enalaprilat, which bears US NIH Compound Identifier 5362032. European Medicines Agency schedules Enalaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06515MIG.

UNSPSC 51432804 Enalaprilat, a Commodity code, encompasses specific pharmaceutical products—in this case a vasodilator medication—that state and local governments procure for emergency medical services, institutional healthcare, and pharmacy benefit programs. State and local opportunities under this code show demand from city fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work involves supplying FDA-compliant medications with defined expiration horizons, maintaining cold-chain or storage requirements, arranging timely delivery and expired-stock replacement, and meeting OSHA hazard communication and federal accessibility documentation standards.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications—including specific drug line items (Labetalol HCI, Epinephrine, Adenosine, Diltiazem) required by Tampa Fire Rescue—with a $40,000 estimated contract value, a firm-price requirement including freight to Tampa, nine-month minimum expiration dates, and a 5 percent SLBE bid discount not to exceed $10,000. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) in April 2026 to explore vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and wholesaler channels, signaling exploratory interest in non-traditional supply models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) with a March 26, 2026 response deadline to establish multiple contracts for generic multi-source pharmaceuticals distributed across state and local facilities in Minnesota and Oregon, requiring NDC-level product specifications, cGMP and DSCSA compliance certification, relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), and a 3 percent administrative fee with performance penalties ranging from $200 to $1,500 per violation.